Live
FierceBiotechCellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPOFierceBiotechBayer buys Perfuse in $2.4B deal for midphase eye disease prospectEndpoints NewsCellCentric raises $220M to get multiple myeloma pill to marketFierceBiotechAfter a decade of hype, Najat Khan is bringing Recursion back down to earthEndpoints NewsBayer to buy Perfuse Therapeutics for $300M upfrontFierceBiotechNovo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditchedFierceBiotechAvalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwindEndpoints NewsNovo Nordisk's Q1 in four words: Pills, pricing, payments and pressureLabiotechSickle cell disease after Casgevy: seven companies to watch in 2026FierceBiotechJ&J’s Ottava surgical robot meets primary endpoints in gastric bypass studyeLifeHER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial contenteLifeCanonical neurodevelopmental trajectories of structural and functional manifolds

Archive

Latest Oldest
Total 10219
Page 312 / 568
Query --